Page 2115 - Williams Hematology ( PDFDrive )

2090 Part XII: Hemostasis and Thrombosis Chapter 121: Acquired Qualitative Platelet Disorders 2091

201. Byrd JC, Furman RR, Coutre SE, et al: Targeting BTK with ibrutinib in relapsed chronic 238. Villmow T, Kemkes-Matthes B, Matzdorff AC: Markers of platelet activation and
lymphocytic leukemia. N Engl J Med 369(1):32–42, 2013. platelet-leukocyte interaction in patients with myeloproliferative syndromes. Thromb
202. Wang ML, Rule S, Martin P, et al: Targeting BTK with ibrutinib in relapsed or refractory Res 108(2–3):139–145, 2002.
mantle-cell lymphoma. N Engl J Med 369(6):507–516, 2013. 239. Falanga A, Marchetti M, Vignoli A, et al: Leukocyte-platelet interaction in patients with
203. Advani RH, Buggy JJ, Sharman JP, et al: Bruton tyrosine kinase inhibitor ibrutinib essential thrombocythemia and polycythemia vera. Exp Hematol 33(5):523–530, 2005.
(PCI-32765) has significant activity in patients with relapsed/refractory B-cell malig- 240. Maldonado JE, Pintado T, Pierre RV: Dysplastic platelets and circulating megakaryo-
nancies. J Clin Oncol 31(1):88–94, 2013. cytes in chronic myeloproliferative diseases. I. The platelets: Ultrastructure and peroxi-
204. Levade M, David E, Garcia C, et al: Ibrutinib treatment affects collagen and von Wille- dase reaction. Blood 43(6):797–809, 1974.
brand Factor-dependent platelet functions. Blood 124(26):3991–3995, 2014. 241. Bautista AP, Buckler PW, Towler HM, et al: Measurement of platelet life-span in normal
205. Quek LS, Bolen J, Watson SP: A role for Bruton’s tyrosine kinase (Btk) in platelet activa- subjects and patients with myeloproliferative disease with indium oxine labelled plate-
tion by collagen. Curr Biol 8(20):1137–1140, 1998. lets. Br J Haematol 58(4):679–687, 1984.
206. Atkinson BT, Ellmeier W, Watson SP: Tec regulates platelet activation by GPVI in the 242. Ginsberg AD: Platelet function in patients with high platelet counts. Ann Intern Med
absence of Btk. Blood 102(10):3592–3599, 2003. 82:506–511, 1975.
207. Cohen H, Neild GH, Patel R, et al: Evidence for chronic platelet hyperaggregability 243. Janson PA, Jubelirer SJ, Weinstein MS, Deykin D: Treatment of bleeding tendency in
and in vivo activation in cyclosporin-treated renal allograft recipients. Thromb Res uremia with cryoprecipitate. N Engl J Med 303:1318, 1980.
49(1):91–101, 1988. 244. Pareti FI, Gugliotta L, Mannucci L, et al: Biochemical and metabolic aspects of plate-
208. Thomson C, Forbes CD, Prentice CR: A comparison of the effects of antihistamines on let dysfunction in chronic myeloproliferative disorders. Thromb Haemost 47(2):84–89,
platelet function. Thromb Diath Haemorrh 30(3):547–556, 1973. 1982.
209. Platelet function during long-term treatment with ketanserin of claudicating patients 245. Schafer AI: Deficiency of platelet lipoxygenase activity in myeloproliferative disorders.
with peripheral atherosclerosis. A multi-center, double-blind, placebo-controlled trial. N Engl J Med 306(7):381–386, 1982.
The PACK Trial Group. Thromb Res 55(1):13–23, 1989. 246. Sugiyama T, Okuma M, Ushikubi F, et al: A novel platelet aggregating factor found in a
210. Parvez Z, Moncada R, Fareed J, Messmore HL: Antiplatelet action of intravascular con- patient with defective collagen-induced platelet aggregation and autoimmune throm-
trast media. Implications in diagnostic procedures. Invest Radiol 19(3):208–211, 1984. bocytopenia. Blood 69:1712–1720, 1987.
211. Rao AK, Rao VM, Willis J, et al: Inhibition of platelet function by contrast media: 247. Kaywin P, McDonough M, Insel PA, Shattil SJ: Platelet function in essential thrombo-
Iopamidol and ioxaglate versus iothalamate. Work in progress. Radiology 156(2):311– cythemia: Decreased epinephrine responsiveness associated with a deficiency of plate-
313, 1985. let alpha-adrenergic receptors. N Engl J Med 299:505–509, 1978.
212. Goodnight SH Jr, Harris WS, Connor WE: The effects of dietary omega 3 fatty acids 248. Swart SS, Pearson D, Wood JK, Barnett DB: Functional significance of the platelet
on platelet composition and function in man: A prospective, controlled study. Blood alpha2-adrenoceptor: Studies in patients with myeloproliferative disorders. Thromb Res
58(5):880–885, 1981. 33(5):531–541, 1984.
213. Moncada S, Higgs EA: Arachidonate metabolism in blood cells and the vessel wall. Clin 249. Handa M, Watanabe K, Kawai Y, et al: Platelet unresponsiveness to collagen: Involve-
Haematol 15(2):273–292, 1986. ment of glycoprotein Ia-IIa (alpha 2 beta 1 integrin) deficiency associated with a mye-
214. Leaf A, Weber PC: Cardiovascular effects of n-3 fatty acids. N Engl J Med 318(9):549– loproliferative disorder. Thromb Haemost 73(3):521–528, 1995.
557, 1988. 250. Moore SF, Hunter RW, Harper MT, et al: Dysfunction of the PI3 kinase/Rap1/integrin
215. Hammerschmidt DE: Szechwan purpura. N Engl J Med 302(21):1191–1193, 1980. alpha(IIb)beta(3) pathway underlies ex vivo platelet hypoactivity in essential thrombo-
216. Srivastava KC: Onion exerts antiaggregatory effects by altering arachidonic acid metab- cythemia. Blood 121(7):1209–1219, 2013.
olism in platelets. Prostaglandins Leukot Med 24(1):43–50, 1986. 251. Malpass TW, Savage B, Hanson SR, et al: Correlation between prolonged bleeding time
217. Apitz-Castro R, Escalante J, Vargas R, Jain MK: Ajoene, the antiplatelet principle of and depletion of platelet dense granule ADP in patients with myelodysplastic and mye-
garlic, synergistically potentiates the antiaggregatory action of prostacyclin, forskolin, loproliferative disorders. J Lab Clin Med 103(6):894–904, 1984.
indomethacin and dipyridamole on human platelets. Thromb Res 42(3):303–311, 1986. 252. Mohri H: Acquired von Willebrand disease and storage pool disease in chronic myelo-
218. Srivastava KC: Extracts from two frequently consumed spices—cumin (Cuminum cytic leukemia. Am J Hematol 22(4):391–401, 1986.
cyminum) and turmeric (Curcuma longa)—inhibit platelet aggregation and alter 253. Walsh PN, Murphy S, Barry WE: The role of platelets in the pathogenesis of thrombosis
eicosanoid biosynthesis in human blood platelets. Prostaglandins Leukot Essent Fatty and hemorrhage in patients with thrombocytosis. Thromb Haemost 38(4):1085–1096,
Acids 37(1):57–64, 1989. 1977.
219. Pearson TC: The risk of thrombosis in essential thrombocythemia and polycythemia 254. Kaplan R, Gabbeta J, Sun L, et al: Combined defect in membrane expression and activa-
vera. Semin Oncol 29(3 Suppl 10):16–21, 2002. tion of platelet GPIIb–IIIa complex without primary sequence abnormalities in myelo-
220. Kessler CM: Propensity for hemorrhage and thrombosis in chronic myeloproliferative proliferative disease. Br J Haematol 111(3):954–964, 2000.
disorders. Semin Hematol 41(2 Suppl 3):10–14, 2004. 255. Berndt MC, Kabral A, Grimsley P, et al: An acquired Bernard-Soulier-like platelet
221. Tefferi A: Polycythemia vera and essential thrombocythemia: 2013 update on diagno- defect associated with juvenile myelodysplastic syndrome. Br J Haematol 68(1):97–101,
sis, risk-stratification, and management. Am J Hematol 88(6):507–516, 2013. 1988.
222. Schafer AI: Thrombocytosis. N Engl J Med 350(12):1211–1219, 2004. 256. Cooper B, Schafer AI, Puchalsky D, Handin RI: Platelet resistance to prostaglandin D2
223. Alfirevic A, Duncan A, You J, et al: Recombinant factor VII is associated with worse in patients with myeloproliferative disorders. Blood 52(3):618–626, 1978.
survival in complex cardiac surgical patients. Ann Thorac Surg 98(2):618–624, 2014. 257. Moore A, Nachman RL: Platelet Fc receptor. Increased expression in myeloproliferative
224. Wasserman LR, Gilbert HS: The treatment of polycythemia vera. Med Clin North Am disease. J Clin Invest 67(4):1064–1071, 1981.
50(6):1501–1518, 1966. 258. Bolin RB, Okumura T, Jamieson GA: Changes in distribution of platelet membrane gly-
225. Murphy S: Polycythemia vera. Dis Mon 38(3):153–212, 1992. coproteins in patients with myeloproliferative disorders. Am J Hematol 3:63–71, 1977.
226. Carobbio A, Finazzi G, Antonioli E, et al: Thrombocytosis and leukocytosis interac- 259. Eche N, Sie P, Caranobe C, et al: Platelets in myeloproliferative disorders. III: Glyco-
tion in vascular complications of essential thrombocythemia. Blood 112(8):3135–3137, protein profile in relation to platelet function and platelet density. Scand J Haematol
2008. 26(2):123–129, 1981.
227. Schafer AI: Essential thrombocythemia. Prog Hemost Thromb 10:69–96, 1990. 260. Thibert V, Bellucci S, Cristofari M, et al: Increased platelet CD36 constitutes a common
228. Elliott MA, Tefferi A: Pathogenesis and management of bleeding in essential thrombo- marker in myeloproliferative disorders. Br J Haematol 91(3):618–624, 1995.
cythemia and polycythemia vera. Curr Hematol Rep 3(5):344–351, 2004. 261. Moliterno AR, Hankins WD, Spivak JL: Impaired expression of the thrombopoietin
229. Kessler CM, Klein HG, Havlik RJ: Uncontrolled thrombocytosis in chronic myelopro- receptor by platelets from patients with polycythemia vera. N Engl J Med 338(9):572–
liferative disorders. Br J Haematol 50(1):157–167, 1982. 580, 1998.
230. McIntyre KJ, Hoagland HC, Silverstein MN, Petitt RM: Essential thrombocythemia in 262. Humbert M, Nurden P, Bihour C, Pet al: Ultrastructural studies of platelet aggregates
young adults. Mayo Clin Proc 66(2):149–154, 1991. from human subjects receiving clopidogrel and from a patient with an inherited defect
231. Michiels JJ, Berneman Z, Gadisseur A, et al: Immune-mediated etiology of acquired of an ADP-dependent pathway of platelet activation. Arterioscler Thromb Vasc Biol
von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal 16(12):1532–1543, 1996.
gammopathy: Therapeutic implications. Semin Thromb Hemost 32(6):577–588, 2006. 263. Rocca B, Ciabattoni G, Tartaglione R, et al: Increased thromboxane biosynthesis in
232. Carobbio A, Antonioli E, Guglielmelli P, et al: Leukocytosis and risk stratification essential thrombocythemia. Thromb Haemost 74(5):1225–1230, 1995.
assessment in essential thrombocythemia. J Clin Oncol 26(16):2732–2736, 2008. 264. Landolfi R, Ciabattoni G, Patrignani P, et al: Increased thromboxane biosynthesis in
233. Budde U, Schaefer G, Mueller N, et al: Acquired von Willebrand’s disease in the myelo- patients with polycythemia vera: Evidence for aspirin-suppressible platelet activation in
proliferative syndrome. Blood 64(5):981–985, 1984. vivo. Blood 80(8):1965–1971, 1992.
234. Tiede A, Rand JH, Budde U, et al: How I treat the acquired von Willebrand syndrome. 265. Tripodi A, Chantarangkul V, Gianniello F, et al: Global coagulation in myeloprolifera-
Blood 117(25):6777–6785, 2011. tive neoplasms. Ann Hematol 92(12):1633–1639, 2013.
235. Hernandez-Boluda JC, Gomez M: Target hematologic values in the management of 266. Marchetti M, Tartari CJ, Russo L, et al: Phospholipid-dependent procoagulant activity
essential thrombocythemia and polycythemia vera. Eur J Haematol 94(1):4–11, 2015. is highly expressed by circulating microparticles in patients with essential thrombo-
236. Landolfi R, Di Gennaro L, Barbui T, et al: Leukocytosis as a major thrombotic risk cythemia. Am J Hematol 89(1):68–73, 2014.
factor in patients with polycythemia vera. Blood 109(6):2446–2452, 2007. 267. Cazzola M, Kralovics R: From Janus kinase 2 to calreticulin: The clinically rele-
237. Gangat N, Strand J, Li CY, et al: Leucocytosis in polycythaemia vera predicts both infe- vant genomic landscape of myeloproliferative neoplasms. Blood 123(24):3714–3719,
rior survival and leukaemic transformation. Br J Haematol 138(3):354–358, 2007. 2014.

Kaushansky_chapter 121_p2073-2096.indd 2090 9/18/15 10:28 AM